Refine your search
Collections
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Кatya, Todorova
- Levels of Adipokines–Adiponectin and Resistin in Patients with Metabolic Syndrome and Newly Diagnosed Diabetes Mellitus Type 2
Abstract Views :483 |
PDF Views:150
Authors
Affiliations
1 Medical University Pleven, UMHAT “D-r Georgi Stranski”, Clinic of Endocrinology and Metabolic Diseases, Medico-Diagnostic Laboratory of Immunology, BG
2 Medical University Pleven, UMHAT “D-r Georgi Stranski”, Medico-Diagnostic Laboratory of Immunology, BG
1 Medical University Pleven, UMHAT “D-r Georgi Stranski”, Clinic of Endocrinology and Metabolic Diseases, Medico-Diagnostic Laboratory of Immunology, BG
2 Medical University Pleven, UMHAT “D-r Georgi Stranski”, Medico-Diagnostic Laboratory of Immunology, BG
Source
SMU Medical Journal, Vol 4, No 2 (2017), Pagination: 140-152Abstract
It has been recently proven, that the adipose tissue is not just a passive energy depot, but rather active endocrine organ – adipocytes are expressing on their surface multiple receptors and are releasing adipokines, hormones, cytokines, growth factors. Aim of the present study was to examine the serum levels of adipokines – adiponectin and resistin in patients with metabolic syndrome (MS) and newly diagnosed diabetes mellitus type 2 (NDDMt2). A prospective, comparative, observational study was performed. In 45 subjects with MS and NDDMt2 (n1=45) and 35 clinical health subjects (n2=35) were measured and compared the serum levels of adipokines – adiponectin and resistin. Two homoeostasis models assessment of insulin resistance (HOMA-IR) and of β-cell function (HOMA-%В) were calculated. A significantly lower level of adiponectin was detected in patients with MS and NDDMt2 in comparison whit the control group (n1=0.97±0.47 vs. n2=1.96±0.73 μg/ml; p=0.005). A significantly higher level of resistin was found in patients with MS and NDDMt2 in comparison whit controls (n1=1.85±0.70 vs. n2=0.71±0.31 ng/ml; p=0.025). We have found negative correlations between concentration of adiponectin and serum levels of resistin, BMI and waist circumference in MS and NDDMt2 patients. The resistin was positively correlated with BMI and waist circumference, and was negatively correlated with HDL-cholesterol in MS and NDDMt2 patients.Patients with MS and NDDMt2 exhibited significantly changes in levels of adiponectin and resistin. Indicated adipokines may have predictive value of progression from normal to pathological carbohydrate metabolism.Keywords
Metabolic Syndrome, Newly Diagnosed Diabetes Mellitus Type 2, Adiponectin, Resistin.Full Text
References
- Galik S, Oakhill J and Steinberg G. (2010) Adipose tissue as an endocrine organ. Molecular and Cellular Endocrinology. 316(2),129-139.
- Karastegiou K and Mohamed-AliV. (2010) The autocrine and paracrine roles of adipokines. Molecular and Cellular Endocrinology. 318(3),1784-1792.
- Deng Y and Scherer P. (2010) Adipokines as novel biomarkers and regulators of the metabolic syndrome. Diabetes and Obesity.1221, 1-19.
- Kadowaki T and Yamauchi J. (2005) Adiponectin and adiponectin receptors. Endocrin Rev. 26(3), 439-451.
- Yamauchi T, Kamon J and Minokoshi Kamon J. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 8(10),1288-1295.
- Cook JR and Semple RK. (2010) Hypoadiponectinemia - cause or consequence of human “Insulin resistance”? J.Clin Endocrinol Metab. 95(4),1544-1554.
- Rabe K, Lehrke M, Parhofer KG and Broedi UC. (2008) Adipokines and insulin resistance Mol Med. 14(11-12), 741-751.
- Hoffstedt J, Arvidsson E, Sjolin E, Wahlen K and Arner P. (2004) Adipose tissue, adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab. 89,1391-1396.
- Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y and Pratley RE. (2011) Hypoadiponectynaemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinaemia. J Clin Endocrinol Metab. 86(5),1930-1935.
- Mojiminiyo OA, Abdela NA, Arouj M. (2007) Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int J Obese.31,213-220.
- Rasouli N and Kern P. (2008) Adipocytokines and metabolic complications of obesity. J.Clin Endocrinol Metab. 93(11), S64-S73.
- Vasilescu R, Ifrim S and Trigoviste C. (2011) Relationship between plasma adipokines, inflammation, insulin resistance and subclinical atherosclerosis in newly diagnosed type 2 diabetes. Journal of Diabetes Mellitus.1(2),17-25.
- Hajer G, Graaf Y, Olijhoek J, Edlinger M and Visseren F. (2007) Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J. 154(4), 749-756.
- Al-Hamodi Z, Al-Habori M, Al-Meeri M and Riyadh SA. (2014) Association of adipokines, leptin/adiponectin and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetology & Metabolic Syndrome.6(1), 99-107.
- Steppan CM, Bailey Sh, Bhat S, Brown E and Banerjee R. (2001) The hormone resistin links obesity to diabetes. Nature. 409, 307-312.
- Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK and Harrington WW. (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 276 (28), 25651–25653.
- Koleva D, Orbetzova M and Atanasova P. (2013) Adipose tissue hormones and appetite and body weight regulators in insulin resistance. Folia medica. 55(11),25-32.
- DogruT, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI and Gene H. (2007) Plasma resistin levels in patients with newly diagnosed untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Research and Clinical Practice. 76(1), 2-7.
- Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L and Catapano AL. (2007) Plasma resistin levels correlate with determinants of the metabolic syndrome. European Journal of Endocrinology. 156, 279-284.
- Utzschneider KM, Carr DB,Tong J,Wallace TM, Hull RL and Zrika S et al. (2005) Resistin is not associated with insulin sensitivity or metabolic syndrome in humans. Diabetologia. 48(11), 2330-2333.
- International Diabetes Federation. (2010) The IDF Consensus worldwide definition of the metabolic syndrome.
- World Health Organization. (2011) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 34(Suppl1), 62-69.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC. (1985) Homeostasis model assessment: insulin resistance and beta-cells function from fasting plasma glucose and insulin concentration in man. Diabetologia. 28(7), 412-419.
- Silha V, Kresk M, Skrha J, Sucharda P, Nyomba B and Murphy L. (2003) Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. European Journal of Endocrinology. 149(3), 331-335.
- Wannamethee S, Lowe G, Rumley A, Cherry L, Whincup P and Sattar N. (2007) Adipokines and Risk of Type 2 Diabetes in Older Men. Diabetes Care. 5(30), 1200-1205.
- Rayanova G, Ganeva S, Todorova К, Lukanov Ts and Blajeva S. (2015) Adiponectin, leptin and resistin in patients with metabolic syndrome. Endocrinologia. 3(20), 134-143.
- Dunmore J and Brown J. (2013) The role of adipokines in β-cell failure of type 2 diabetes. Journal of Endocrinology. 216(1), 37-45.
- Choi KL, Lee JM and Lee KW. (2004) Serum adiponectin concentracions predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf). 61(1),75-80.
- Lee JM, Kim SR, Joo SJ, Hong OK, Son HS and Chang SA. (2009) The relationship between adipokines, metabolic parameters and insulin resistance in patients with Metabolic syndrome and Type 2 Diabetes. The Journal of International Medical Research. 37,1803-1912.
- Zaidi SI and Shirwany TA. (2015) Relationship of serum resistin with insulin resistance and obesity. J Ayub Med Col Abbottabad. 27(3), 552-555.
- Youn BS,Yu KY, Je PH, Lee NS, Min SS and Youn MY et al. (2004) Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 Diabetes mellitus. J Clin Endocrinol Metab. 89(1), 150-156.
- De Luis DA, Gonzales SM, Conde R, Aller A, Izaola O and Primo D. (2012) Lak of association of serum resistin levels with metabolic syndrome criteria in obese patients. Clin Biochem. 44(16), 1280-1283.
- Koleva D, Orbetzova M, Nygolova V, Konsulova S and Atanasova B. (2016) Resistin and Insulin resistance in Women with Polycystic Ovary Syndrome. Endocrinology. 4(21), 211-222.